Momegen (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene expression to suppress pro‑inflammatory cytokines, inhibit leukocyte migration, and reduce the activity of enzymes that generate inflammatory mediators. This results in decreased inflammation and immune response at the site of application.

The specific dose and frequency of Momegen are determined by the prescribing healthcare professional based on the severity of the condition, the area of skin involved, and patient factors. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for mometasone furoate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To order Momegen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Momegen (mometasone furoate) is a high‑potency topical corticosteroid, offering strong anti‑inflammatory effects with once‑daily application for many patients. Compared with lower‑potency steroids like hydrocortisone, it may achieve faster symptom control but requires careful monitoring to avoid local side effects.

Momegen should be stored at temperatures below 25 °C in its original packaging. Keep the product away from moisture, direct sunlight, and heat sources. Do not freeze. Ensure the container is tightly closed when not in use.

Momegen is applied topically to the affected skin area. Clean and gently dry the skin, then spread a thin layer of the product over the lesion, usually once daily or as directed by the prescriber. Avoid applying to broken skin, eyes, or mucous membranes unless instructed.

Serious risks include skin atrophy, telangiectasia, secondary infections, and systemic corticosteroid effects such as adrenal suppression when used over large areas or for prolonged periods. Patients should report any unusual thinning of the skin, persistent infections, or signs of hormonal imbalance to their doctor.

Momegen should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated on infected skin that has not been treated, on large surface areas for extended periods, and in infants unless specifically prescribed.